Literature DB >> 30707770

Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics.

Cécile Ollivier1, Andrew Thomson1, Efthymios Manolis1, Kevin Blake1, Kristin E Karlsson2, Catherijne A J Knibbe3,4, Gérard Pons5, Robert Hemmings6.   

Abstract

Adopted guidelines reflect a harmonised European approach to a specific scientific issue and should reflect the most recent scientific knowledge. However, whilst EU regulations are mandatory for all member states and EU directives must be followed by national laws in line with the directive, EMA guidelines do not have legal force and alternative approaches may be taken, but these obviously require more justification. This new series of the BJCP, developed in collaboration with the EMA, aims to address this issue by providing an annotated version of some relevant EMA guidelines and regulatory documents by experts. Hopefully, this will help in promoting their diffusion and in opening a forum for discussion with our readers.
© 2019 The British Pharmacological Society.

Mesh:

Year:  2019        PMID: 30707770      PMCID: PMC6422728          DOI: 10.1111/bcp.13883

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Pediatric information in drug product labeling.

Authors:  Aaron N Sachs; Debbie Avant; Catherine S Lee; William Rodriguez; M Dianne Murphy
Journal:  JAMA       Date:  2012-05-09       Impact factor: 56.272

2.  Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.

Authors:  Margaret Gamalo-Siebers; Jasmina Savic; Cynthia Basu; Xin Zhao; Mathangi Gopalakrishnan; Aijun Gao; Guochen Song; Simin Baygani; Laura Thompson; H Amy Xia; Karen Price; Ram Tiwari; Bradley P Carlin
Journal:  Pharm Stat       Date:  2017-04-27       Impact factor: 1.894

Review 3.  Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies.

Authors:  Jessica K Roberts; Chris Stockmann; Alfred Balch; Tian Yu; Robert M Ward; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Anaesth       Date:  2015-01-09       Impact factor: 2.556

4.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

Review 5.  Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.

Authors:  Yeruk Mulugeta; Jeffrey S Barrett; Robert Nelson; Abel Tilahun Eshete; Alvina Mushtaq; Lynne Yao; Nicole Glasgow; Andrew E Mulberg; Daniel Gonzalez; Dionna Green; Jeffry Florian; Kevin Krudys; Shirley Seo; Insook Kim; Dakshina Chilukuri; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

6.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop.

Authors:  E Manolis; S Rohou; R Hemmings; T Salmonson; M Karlsson; P A Milligan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-02-27

7.  Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study.

Authors:  E Kimland; P Nydert; V Odlind; Y Böttiger; S Lindemalm
Journal:  Acta Paediatr       Date:  2012-03-24       Impact factor: 2.299

Review 8.  Pharmacokinetic studies in children: recommendations for practice and research.

Authors:  Charlotte I S Barker; Joseph F Standing; Lauren E Kelly; Lauren Hanly Faught; Allison C Needham; Michael J Rieder; Saskia N de Wildt; Martin Offringa
Journal:  Arch Dis Child       Date:  2018-04-19       Impact factor: 3.791

9.  Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Authors:  Elisa A M Calvier; Elke H J Krekels; Pyry A J Välitalo; Amin Rostami-Hodjegan; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

10.  Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.

Authors:  Elisa A M Calvier; Elke H J Krekels; Huixin Yu; Pyry A J Välitalo; Trevor N Johnson; Amin Rostami-Hodjegan; Dick Tibboel; Piet H van der Graaf; Meindert Danhof; Catherijne A J Knibbe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-05
View more
  11 in total

Review 1.  Developmental Pharmacodynamics and Modeling in Pediatric Drug Development.

Authors:  Laurie S Conklin; Eric P Hoffman; John van den Anker
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

2.  Scientific and Regulatory Considerations for an Ontogeny Knowledge Base for Pediatric Clinical Pharmacology.

Authors:  Gilbert J Burckart; Shirley Seo; Aaron C Pawlyk; Susan K McCune; Lynne P Yao; George P Giacoia; Yaning Wang; Issam Zineh
Journal:  Clin Pharmacol Ther       Date:  2020-01-26       Impact factor: 6.903

3.  Could Postnatal Age-Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?

Authors:  Tao Liu; Tamorah R Lewis; Jason N Moore; Walter K Kraft; Estelle B Gauda; David Sartori; David E Moody; Jogarao V S Gobburu; Vijay Ivaturi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-05-10

4.  New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.

Authors:  Cécile Ollivier; Haihao Sun; Wayne Amchin; Maurice Beghetti; Rolf M F Berger; Stefanie Breitenstein; Christine Garnett; Ninna Gullberg; Patrik Hassel; Dunbar Ivy; Steven M Kawut; Agnes Klein; Catherine Lesage; Marek Migdal; Barbara Nije; Michal Odermarsky; James Strait; Pieter A de Graeff; Norman Stockbridge
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

5.  Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control.

Authors:  Annette Kopp-Schneider; Silvia Calderazzo; Manuel Wiesenfarth
Journal:  Biom J       Date:  2019-07-02       Impact factor: 2.207

Review 6.  Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation.

Authors:  Hans-Georg Eichler; Franz Koenig; Peter Arlett; Harald Enzmann; Anthony Humphreys; Frank Pétavy; Brigitte Schwarzer-Daum; Bruno Sepodes; Spiros Vamvakas; Guido Rasi
Journal:  Clin Pharmacol Ther       Date:  2019-10-01       Impact factor: 6.875

Review 7.  Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Timothy J Carrothers; Todd Riccobene; Gregory G Stone; Michal Kantecki
Journal:  Paediatr Drugs       Date:  2021-08-31       Impact factor: 3.022

8.  Description of a clinical decision support tool with integrated dose calculator for paediatrics.

Authors:  Lukas Higi; Karin Käser; Monika Wälti; Michael Grotzer; Priska Vonbach
Journal:  Eur J Pediatr       Date:  2021-09-15       Impact factor: 3.860

Review 9.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

10.  The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.

Authors:  Phylinda L S Chan; Lynn McFadyen; Andrea Quaye; Heidi Leister-Tebbe; Victoria M Hendrick; Jennifer Hammond; Susan Raber
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.